Hims Peptides: Driving Revenue Growth Ahead of 2026 FDA Review

Hims & Hers Health Inc. May see its peptides business expand as a potential revenue driver following a U.S. Food and Drug Administration review initiated in April 2026, according to multiple financial and healthcare news reports.

The FDA’s decision to evaluate several wellness peptides currently restricted under agency guidance represents an early-stage but meaningful development for the telehealth company, analysts said. Bank of America raised its price target on Hims & Hers stock to $25 from $21 while maintaining a Neutral rating, citing the FDA’s step toward broader peptide access as creating optionality for new revenue streams.

The analyst noted that the FDA’s review could allow Hims & Hers to repurpose existing manufacturing capacity currently used for GLP-1 weight-loss medications toward other peptide-based products, potentially supporting growth as the company transitions from pandemic-era telehealth demand.

Reports indicate that Robert F. Kennedy Jr.’s emerging policy stance on peptides could further support this opportunity, though specific policy details were not outlined in the available sources. The FDA’s evaluation remains in preliminary stages, with analysts emphasizing that no final approval or broad formulary addition has occurred.

Hims & Hers has been expanding beyond its initial telehealth and direct-to-consumer prescription model into broader wellness and preventive care offerings. The peptide review aligns with the company’s stated interest in longevity and preventative medicine, areas where peptide therapies are increasingly being explored for applications such as muscle recovery, cognitive function, and metabolic health.

While the company’s GLP-1 business has driven recent growth, analysts suggest that diversification into peptides could help mitigate reliance on any single product category as the weight-loss drug market evolves with increased competition and potential pricing pressures.

As of mid-April 2026, Hims & Hers stock had shown positive movement following the FDA news, though trading activity reflects cautious optimism given the early stage of the regulatory process. No company commentary on specific peptide products or timelines for potential commercialization was included in the verified reports.

Investors and industry observers are advised to monitor for further FDA guidance, company updates on peptide research or partnerships, and evidence of regulatory progress beyond initial review stages before assessing the full commercial potential of this opportunity.